TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00585221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha 2b (PegIFNa2b);
Description: Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
Study: NCT01798004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02329730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Description: Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
Study: NCT00585221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Continue imatinib until progression.
Study: NCT02509052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02329730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Description: Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Description: Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Description: Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
Study: NCT01236911

Intervention type: OTHER
Intervention: Calcium Measurement
Description: after moderate-severe TBI (less as 24 hrs)
Study: NCT03656588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
Description: a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine scrub and ChloraPrep alone
Description: Iodine scrub and ChloraPrep alone
Study: NCT02354794

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One form of arginine
Description: 3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
Study: NCT02342327

Intervention type: OTHER
Group type: OTHER
Intervention: switch to non-menthol cigarettes prior to cessation attempt

Intervention type: OTHER
Group type: OTHER
Intervention: continue smoking menthol cigarettes prior to cessation attempt
Study: NCT02113605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
Study: NCT04016753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: 30 mg(6ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin
Description: 1.5 mg Norethindrone and 30ug ethinyl estradiol
Study: NCT00968994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The exSALT™ SD7 Wound Dressing
Description: The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xeroform® Petrolatum Dressing
Description: Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
Study: NCT01533389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
Study: NCT00995826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8958
Description: Inhaled CS-8958

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo
Study: NCT01539694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LD118033 contact lens
Description: Multifocal contact lens worn on a daily wear basis for 1 week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision multifocal contact lens
Description: PureVision multifocal contact lens worn on a daily wear basis for 1 week.
Study: NCT01119612

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: Daily oral dose of 60 mg from enrollment until delivery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose from enrollment until delivery
Study: NCT02385045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-scan
Description: i-scan function is located on the head of the Pentax endoscopes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: narrow band imaging
Description: narrow band imaging function is located on the head of Olympus endoscopes
Study: NCT02297477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atovaquone-proguanil
Description: A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate-atovaquone-proguanil
Description: A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
Study: NCT01793649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5737
Description: A single dose of GS-5737 in 2.8% saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5737
Description: A single dose of GS-5737 in 2.8% saline
Study: NCT02894918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180ug/0.5ml,hypodermic injection once a week
Study: NCT01883830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gaming therapy (Xbox)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic balance platform (Biodex)
Study: NCT03683108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol and Carbossimetyl Beta Glucan
Description: Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
Study: NCT04256070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and tele-consultation
Description: education and tele-consultation based on Watson's Human Care Theory
Study: NCT03019822

Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: 100ug per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: 100ug per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: 100ug per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: 100ug per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Amphetamine
Description: 40.3mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Amphetamine
Description: 40.3mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Amphetamine
Description: 40.3mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Amphetamine
Description: 40.3mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs
Study: NCT01955733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500
Study: NCT04782024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7-Keto 50mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7-Keto 25mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00733408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study: NCT02965547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning equipment
Description: The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous blood collection
Description: Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dCA measurement
Description: Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
Study: NCT04911530

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02267811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthodontic Treatment
Description: Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthodontic Treatment
Description: Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse™
Description: Participants carry out daily OrthoPulse™ treatments at home.
Study: NCT02652520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HEMO2Life® use in organ preservation solution
Description: The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
Study: NCT04232124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension Management Model
Description: 1. Blood Pressure readings by barbers~2. Clinical Pharmacist evaluation and counseling~3. Blood pressure measurement~4. Point of care basic metabolic panel measurement
Study: NCT02135471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acellular dermal matrix graft
Description: On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acellular dermal matrix graft
Description: On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enamel matrix derivative
Description: On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
Study: NCT03043131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte A
Description: Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate
Description: Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
Study: NCT02917304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110A vaccine
Description: 0.5mL, Intramuscular
Study: NCT02301884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergen extract
Description: Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
Study: NCT01694641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: time-lapse morphokinetic evaluation
Description: embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
Study: NCT04492202

Intervention type: OTHER
Intervention: Survey
Description: The survey will be sent to health professionals via online link.

Intervention type: OTHER
Intervention: Survey
Description: The survey will be sent to health professionals via online link.
Study: NCT02734355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80 mg and amlodipine 5 mg
Study: NCT00878085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Therapy Device
Description: 3x a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: 3x a week for 4 weeks
Study: NCT03599024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCEA
Description: The patients were able to control the administration of analgesics by themselves.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-PCEA
Description: The patients were receiving analgesics according to the physician's prescription.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement
Description: All patients enrolled in the study were indicated for total hip replacement surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: All patients enrolled in the study were indicated for total hip replacement surgery.
Study: NCT02976428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensor Guided Soft Tissue Balancing
Description: Primary TKR with soft tissue balancing with a sensor guided device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Soft Tissue Balancing
Description: Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
Study: NCT03552315

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbonated water with amino acids and chromium
Description: The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Carbonated Water
Description: The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
Study: NCT04398498

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: TruGraf® Testing
Description: 5 mL collection PAXgene blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: TruGraf® Testing
Description: 5 mL collection PAXgene blood sample
Study: NCT01852110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7622
Description: MK-7622 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7622
Description: MK-7622 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7622
Description: MK-7622 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7622
Description: MK-7622 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MK-7622 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MK-7622 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AChEI
Description: One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AChEI
Description: One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AChEI
Description: One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AChEI
Description: One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally
Study: NCT04422041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time to discharge less than 24 hours
Description: Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discharge time between 24 and 48 hours
Description: Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
Study: NCT02734355

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for telmisartan and amlodipine)
Description: Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet